Eikon Takes TLR7/8 Agonist Into Phase III With Latest VC Mega-Round

The company is moving its toll-like receptor 7/8 agonist into late-stage development for melanoma as it closes a $350.7m series D venture funding round.

Screen display representing venture capital investment — • Source: Shutterstock

Eikon Therapeutics has raised another venture capital mega-round – bringing its total funding to date to $1.1bn – to build what it calls a “21st century biotechnology company.” The new financing will allow the Roger Perlmutter-helmed company to move its lead asset, EIK1001, into Phase III development.

Hayward, CA-based Eikon announced 26 February that it closed a $350.7m series D funding round. The EIK1001 trial is a placebo-controlled Phase II/III study that compares the drug combined with...

Key Takeaways

Eikon Therapeutics closed a $350.7m series D funding round, bringing the total amount of venture capital raised to date to $1.1bn.
The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

22 May 2025

• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

21 May 2025

• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

20 May 2025

• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Hengrui Set For Biggest Biopharma IPO So Far This Year

15 May 2025

• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

21 May 2025

• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.